These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28919300)

  • 1. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer.
    Nelson ER
    Mol Cell Endocrinol; 2018 May; 466():73-80. PubMed ID: 28919300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.
    He S; Nelson ER
    Maturitas; 2017 Oct; 104():29-35. PubMed ID: 28923174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer and (25R)-26-hydroxycholesterol.
    Javitt NB
    Steroids; 2015 Dec; 104():61-4. PubMed ID: 26299212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol and breast cancer pathophysiology.
    Nelson ER; Chang CY; McDonnell DP
    Trends Endocrinol Metab; 2014 Dec; 25(12):649-55. PubMed ID: 25458418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.
    Raza S; Ohm JE; Dhasarathy A; Schommer J; Roche C; Hammer KD; Ghribi O
    Mol Cell Biochem; 2015 Dec; 410(1-2):187-95. PubMed ID: 26350565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer.
    McDonnell DP; Chang CY; Nelson ER
    Climacteric; 2014 Dec; 17 Suppl 2(0 2):60-5. PubMed ID: 25320023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver X receptor as a drug target for the treatment of breast cancer.
    Wu Y; Yu DD; Yan DL; Hu Y; Chen D; Liu Y; Zhang HD; Yu SR; Cao HX; Feng JF
    Anticancer Drugs; 2016 Jun; 27(5):373-82. PubMed ID: 26872310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.
    Nelson ER; Wardell SE; Jasper JS; Park S; Suchindran S; Howe MK; Carver NJ; Pillai RV; Sullivan PM; Sondhi V; Umetani M; Geradts J; McDonnell DP
    Science; 2013 Nov; 342(6162):1094-8. PubMed ID: 24288332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 27-hydroxycholesterol decreases cell proliferation in colon cancer cell lines.
    Warns J; Marwarha G; Freking N; Ghribi O
    Biochimie; 2018 Oct; 153():171-180. PubMed ID: 30009860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling.
    DuSell CD; McDonnell DP
    Trends Pharmacol Sci; 2008 Oct; 29(10):510-4. PubMed ID: 18722677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-adopting classical nuclear receptors by cholesterol metabolites.
    Umetani M
    J Steroid Biochem Mol Biol; 2016 Mar; 157():20-6. PubMed ID: 26563834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.
    Wu Q; Ishikawa T; Sirianni R; Tang H; McDonald JG; Yuhanna IS; Thompson B; Girard L; Mineo C; Brekken RA; Umetani M; Euhus DM; Xie Y; Shaul PW
    Cell Rep; 2013 Nov; 5(3):637-45. PubMed ID: 24210818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer.
    Marwarha G; Raza S; Hammer K; Ghribi O
    Chem Phys Lipids; 2017 Oct; 207(Pt B):108-126. PubMed ID: 28583434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.
    Ma L; Wang L; Nelson AT; Han C; He S; Henn MA; Menon K; Chen JJ; Baek AE; Vardanyan A; Shahoei SH; Park S; Shapiro DJ; Nanjappa SG; Nelson ER
    Cancer Lett; 2020 Nov; 493():266-283. PubMed ID: 32861706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer.
    Baek AE; Nelson ER
    Horm Cancer; 2016 Aug; 7(4):219-28. PubMed ID: 27020054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes.
    Lappano R; Recchia AG; De Francesco EM; Angelone T; Cerra MC; Picard D; Maggiolini M
    PLoS One; 2011 Jan; 6(1):e16631. PubMed ID: 21304949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
    Chen X; Fan Y; Xu B
    Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity, cholesterol metabolism, and breast cancer pathogenesis.
    McDonnell DP; Park S; Goulet MT; Jasper J; Wardell SE; Chang CY; Norris JD; Guyton JR; Nelson ER
    Cancer Res; 2014 Sep; 74(18):4976-82. PubMed ID: 25060521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 27-Hydroxycholesterol: the first identified endogenous SERM.
    Umetani M; Shaul PW
    Trends Endocrinol Metab; 2011 Apr; 22(4):130-5. PubMed ID: 21353593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.